Usmani, S Z
Rodriguez-Otero, P
Bhutani, M
Mateos, M-V
Miguel, J S
Article History
Received: 27 February 2015
Revised: 20 April 2015
Accepted: 7 May 2015
First Online: 12 August 2015
Competing interests
: SZU is a consultant to Celgene, Millennium, Onyx and Sanofi, received research funding from ArrayBioPharma, Celgene, Onyx, Janssen and Pharmacyclics, and speaking honoraria from Celgene, Millennium and Onyx. M-VM has received honoraria of lectures and advisory boards from Janssen, Celgene, Onyx, Millennium and Novartis. JSM participates in advisory boards for Celgene, Millennium, Janssen, Novartis, BMS, Onyx and Sanofi. The remaining authors declare no conflict of interest.